MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.
Olimpia E CurranMichael Tin-Chung PoonLouise GilroyAntonia TorgersenColin SmithWael Al-QsousPublished in: Neuro-oncology advances (2021)
Adjusting for confounders, MYD88-mutant PCNSL appears to show improved survival. While further validation is warranted, detection of MYD88 mutation will aid the identification of patients who may benefit from novel targeted therapies.